By: Catherine Marfin, University of Texas Health Science Center at Houston From: medicalxpress.com A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more efficient ways to detect and treat metastatic breast cancer in humans, UTHealth Houston researchers have discovered. The research was published in Molecular Therapy Oncology and led by Mikhail …
EMA Recommends Generic for Advanced/Metastatic Breast Cancer
By: Sophie Cousins From: medscape.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Palbociclib Viatris (palbociclib, Viatris Limited) for the treatment of locally advanced or metastatic breast cancer. Palbociclib is a cyclin-dependent kinase 4/6 inhibitor designed to slow cancer cell proliferation for patients with hormone receptor (HR)‑positive, human epidermal …
Oral Paclitaxel DHP107 Non-inferior to IV for Metastatic Breast Cancer
From: oncnursingnews.com Patients with HER2-negative metastatic breast cancer may soon have a more convenient treatment option, as the phase 3 OPTIMAL trial (NCT03315364) confirms that DHP107, a novel oral paclitaxel formulation, is non-inferior to traditional intravenous (IV) paclitaxel. From January 2018 to December 2023, researchers at 51 sites across South Korea, China, and Europe evaluated 549 patients to determine if …
Advancing Immunotherapy in Metastatic Cancers: Identifying Mechanisms, Targeting Sanctuaries
By: Jasenka Piljac Zegarac, PhD From: ascopubs.org Key Points: As the use of immunotherapy for the treatment of metastatic cancers advances, challenges remain in understanding the mechanisms of metastasis and why certain tumors spread to specific distant organs. Oncologists still treat metastatic disease based on the original tumor site, and most treatment guidelines often do not consider the specific site …
Low BMI Linked to Progression in HR+/HER2– Breast Cancer Treated With CDK4/6i
By: Vicki Moore, PhD From: cancertherapyadvisor.com A BMI of below 18.5 was associated with progression compared with a reference BMI range of 18.5 to 25 Low body mass index (BMI) is associated with tumor progression in patients with hormone receptor-positive (HR+)/HER2-negative (HER–) metastatic breast cancer being treated with CDK4/6 inhibitor (CDK4/6i) therapy, according to research presented in a poster at …
Aggressive BP Control Linked to Lower Mortality in mBC
By: Jennifer Kulpa From: clinicaloncology.com Hypertension is one of the most common comorbidities in patients with metastatic breast cancer (mBC), yet blood pressure (BP) management is often deprioritized in the context of stage IV disease. A new study suggests that both the choice of antihypertensive regimen and the consistency of use may influence overall mortality in this population (Cancer Med …
Symptoms of Late Stage Metastatic Breast Cancer
From: healthline.com Breast cancer that has spread to other parts of your body may start to cause new symptoms, depending on the location of the metastases. As symptoms develop or progress, treatment and care may also need to change. Metastatic breast cancer occurs when cancer that started in the breast spreads to another part of the body. It’s also known …
Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer
By: Mary Ellen Schneider From: cancertherapyadvisor.com Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic breast cancer, according to findings published in the BMJ. The final analysis of the phase 3 PHILA taril (NCT03863223) demonstrated significant improvements in both progression-free survival (PFS) and overall survival (OS). “Pyrotinib, a small molecule, irreversible, pan-HER …
Pumitamig Plus Chemo Drives Strong Responses Across PD-L1 Subgroups of Metastatic TNBC
By: Ashling Wahner From: onclive.com The VEGF/PD-L1–directed bispecific antibody pumitamig (BNT327/BMS986545) has been shown to restore immune activity and improve outcomes in patients with metastatic triple-negative breast cancer (TNBC), showing strong response rates even in patients with a PD-L1 combined positive score (CPS) lower than 10, according to Sarah Sammons, MD. Previously, data from a phase 1b/2 trial (NCT05918133) conducted …
Can Local Therapy Extend Life in Metastatic Breast Cancer?
By: Frederik Joelving From: medscape.com Women with de novo metastatic breast cancer that is confined to a single distant organ may live longer when they undergo resection of the primary tumor, a large cohort study suggested. The study, of over 22,000 US women with the diagnosis, found that while local therapies were uncommon, they were associated with longer overall survival: …